Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Approval Alert | Olaparib Plus Abiraterone and Prednisone/Prednisolone in BRCA-Mutated mCRPC
Patients with BRCA-mutated metastatic castration-resistant prostate cancer can now receive treatment with olaparib plus abiraterone/prednisone or prednisolone following the combination’s approval by the FDA.
Advertisement
Advertisement
Trending on CancerNetwork
1
Botensilimab/Balstilimab Exhibits Meaningful Activity in Ovarian Cancer
2
FDA Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma
3
Novel Agent Shows Early Activity in Phase 2 Recurrent Thymoma Study
4
CNS Disease and Intracranial Management in EGFR-Mutant mNSCLC
5